dc.contributor.author | Jerome, NP | |
dc.contributor.author | Boult, JKR | |
dc.contributor.author | Orton, MR | |
dc.contributor.author | d'Arcy, J | |
dc.contributor.author | Collins, DJ | |
dc.contributor.author | Leach, MO | |
dc.contributor.author | Koh, D-M | |
dc.contributor.author | Robinson, SP | |
dc.date.accessioned | 2016-10-31T14:08:43Z | |
dc.date.issued | 2016-10-03 | |
dc.identifier.citation | BMC nephrology, 2016, 17 (1), pp. 142 - ? | |
dc.identifier.issn | 1471-2369 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/195 | |
dc.identifier.eissn | 1471-2369 | |
dc.identifier.doi | 10.1186/s12882-016-0356-x | |
dc.description.abstract | BACKGROUND: To investigate the combined use of intravoxel incoherent motion (IVIM) diffusion-weighted (DW) and blood oxygen level dependent (BOLD) magnetic resonance imaging (MRI) to assess rat renal function using a 1.5T clinical platform. METHODS: Multiple b-value DW and BOLD MR images were acquired from adult rats using a parallel clinical coil arrangement, enabling quantitation of the apparent diffusion coefficient (ADC), IVIM-derived diffusion coefficient (D), pseudodiffusion coefficient (D*) and perfusion fraction (f), and the transverse relaxation time T2*, for whole kidney, renal cortex, and medulla. Following the acquisition of two baseline datasets to assess measurement repeatability, images were acquired following i.v. administration of hydralazine, furosemide, or angiotensin II for up to 40 min. RESULTS: Excellent repeatability (CoV <10 %) was observed for ADC, D, f and T2* measured over the whole kidney. Hydralazine induced a marked and significant (p < 0.05) reduction in whole kidney ADC, D, and T2*, and a significant (p < 0.05) increase in D* and f. Furosemide significantly (p < 0.05) increased whole kidney ADC, D, and T2*. A more variable response to angiotensin II was determined, with a significant (p < 0.05) increase in medulla D* and significant (p < 0.05) reduction in whole kidney T2* established. CONCLUSIONS: Multiparametric MRI, incorporating quantitation of IVIM DWI and BOLD biomarkers and performed on a clinical platform, can be used to monitor the acute effects of vascular and tubular modulating drugs on rat kidney function in vivo. Clinical adoption of such functional imaging biomarkers can potentially inform on treatment effects in patients with renal dysfunction. | |
dc.format | Electronic | |
dc.format.extent | 142 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | BIOMED CENTRAL LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Kidney | |
dc.subject | Animals | |
dc.subject | Rats | |
dc.subject | Rats, Sprague-Dawley | |
dc.subject | Oxygen | |
dc.subject | Furosemide | |
dc.subject | Hydralazine | |
dc.subject | Angiotensin II | |
dc.subject | Antihypertensive Agents | |
dc.subject | Vasoconstrictor Agents | |
dc.subject | Diuretics | |
dc.subject | Magnetic Resonance Imaging | |
dc.subject | Diffusion Magnetic Resonance Imaging | |
dc.subject | Reproducibility of Results | |
dc.subject | Diffusion | |
dc.subject | Female | |
dc.title | Modulation of renal oxygenation and perfusion in rat kidney monitored by quantitative diffusion and blood oxygen level dependent magnetic resonance imaging on a clinical 1.5T platform. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-09-26 | |
rioxxterms.versionofrecord | 10.1186/s12882-016-0356-x | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2016-10-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | BMC nephrology | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 17 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Magnetic Resonance | |
icr.researchteam | Pre-Clinical MRI | |
dc.contributor.icrauthor | Boult, Jessica | |
dc.contributor.icrauthor | Collins, David | |
dc.contributor.icrauthor | Leach, Martin | |
dc.contributor.icrauthor | Robinson, Simon | |